Join
Live feed
·
PRReleasevia Quantisnow
Axsome Therapeutics Inc. logo

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

ByQuantisnow·Wall Street's wire, on your screen.
AXSM· Axsome Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXSM (Axsome Therapeutics Inc.) and more on Quantisnow.